Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Biological sex differences behind men's increased cancer risk
Tues August 9th - Underlying biological sex differences rather than behavioural differences could be why men are at greater risk of most cancers than women, according to a new analysis. More
Genetically profile all patients' cancers, say experts
Tues August 9th - The NHS should offer all cancer patients genetic profiling of their cancers to help inform their care and to track how the disease evolves, experts say today. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Algorithm improves risk calculations for prostate cancer

Tuesday March 8th 2022

Using the results from two blood markers can improve the accuracy of risk calculations for prostate cancer, a new study has shown.

Calculating a person’s risk of developing prostate cancer using results from two blood markers would improve the accuracy of screening for the disease, reports a new study led by a UCL researcher.

Research led by UCL, UK, has led to an algorithm that estimates a person’s risk of developing prostate cancer based on age and the levels of two prostate cancer markers, prostate-specific antigen (PSA) and human kalliknein peptidase (hK2).

Writing in the latest edition of the *Journal of Medical Screening*, lead author Professor Sir Nicholas Wald, of UCL Institute of Health Informatics, and colleagues describe comparing blood samples of men who later died after a prostate cancer diagnosis with those who were never diagnosed with the disease, using the algorithm.

They found when they set a risk threshold above which men are counted as “screen positive”, it reduced the number of false positives by three quarters compared to a standard PSA test, while catching the same proportion of cancers.

Prof Wald said: “A key drawback of screening for prostate cancer using a PSA test alone is the higher risk of a false positive, which can lead to an unnecessary, invasive biopsy and the unnecessary treatment of a clinically insignificant cancer that would not have caused harm anyway.

“Our study shows a different screening approach could reduce the number of false positives by three quarters. This would make screening for prostate cancer safer and more accurate, reducing overdiagnosis and overtreatment.

“The next step is to test the feasibility of this approach in practice with a pilot project inviting healthy men for screening. If the project is successful, we believe this approach ought to be considered as part of a national screening programme for all men.”

Co-author Jonathan Bestwick, of Queen Mary University of London, said the approach, which is used in pregnancy screening for certain foetal and maternal health conditions, is innovative for cancer because it screens people on the basis of their overall risk rather than the results of a single test.

For this study, the researchers looked at data and blood samples from more than 21,000 men recruited into the prospective BUPA study more than 40 years ago.

They analysed a number of prostate cancer markers in blood samples of 571 men who later died from or with prostate cancer and compared them to a control group of 2,169 men who were never diagnosed with the disease.

While hK2 was quite a weak marker for prostate cancer on its own, the team found it was relatively independent of PSA. It meant the two together yielded a more accurate test.

All participants who were estimated to have a one in 20 or greater risk of developing prostate cancer in the next five years were counted as “screen positive”.

The team found that if men aged 55 and over were screened at least every five years using this risk cut-off, 90% of cancer cases would be detected. About 1.2% of cases would be false positives.

However, if a PSA test had been used to screen for the disease on its own, in one scenario modelled by the researchers, an 86% detection rate would have been accompanied by a false positive rate of 2%.

The researchers also found that men’s PSA levels were significantly elevated up to 30 years before a prostate cancer diagnosis, suggesting that a cause of prostate cancer plays a role long before it is diagnosed.

Wald N et al. Multi-marker risk-based screening for prostate cancer. *Journal of Medical Screening* 7 March 2022


Tags: Cancer | Men's Health | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)